(Q34656851)

3 August 2017

title

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study (English)

1 reference

relapsing-remitting multiple sclerosis

3 August 2017

0 references

0 references

1 reference

1

Ludwig Kappos

1 reference

3 August 2017

5

Gavin Giovannoni

1 reference

3 August 2017

6

Krzysztof Selmaj

1 reference

3 August 2017

2

Ralf Gold

1 reference

3 August 2017

4

Amit Bar-Or

1 reference

3 August 2017

3

Douglas L Arnold

1 reference

3 August 2017

12

Katherine T Dawson

1 reference

3 August 2017

9

Annie Zhang

1 reference

3 August 2017

Sujata P Sarda

7

1 reference

3 August 2017

Sonalee Agarwal

series ordinal

8

1 reference

3 August 2017

Sarah I Sheikh

series ordinal

10

1 reference

3 August 2017

Emily Seidman

series ordinal

11

1 reference

3 August 2017

publication date

22 October 2013

1 reference

Multiple Sclerosis Journal

3 August 2017

published in

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

243-252

1 reference

The use of quality of life measures in multiple sclerosis research.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Quality of life as a predictor for change in disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

The Goldman Consensus statement on depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

SF-36 health survey update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

An empirical comparison of EQ-5D and SF-6D in liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Quality of life in multiple sclerosis: measuring the disease effects more broadly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

The SF-36 in multiple sclerosis: why basic assumptions must be tested

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513507817

21 January 2018

Identifiers

DOI

10.1177/1352458513507817

1 reference

3 August 2017

1 reference